Society of Infectious Diseases Pharmacists | Strategic Alliance Partners

Cephalosporins are commonly prescribed in the outpatient setting; understanding differences among them is important for pharmacists.

Cefepime-taniborbactam shows promise against resistant infections, but more studies are needed.

As HIV treatment and prevention evolve, the use of long-acting injectables and their role in combating the HIV epidemic grows.

The agency outlines key elements for building effective hospital sepsis programs.

Incorporating AI into pharmacy education is crucial to training on its appropriate use.

Medication therapy management reimbursement can be a driving factor to work toward statin implementation in this patient group.

Pharmacy personnel can be integrated to optimize antimicrobial use.

Outpatient ASPs remain crucial amid rising antimicrobial resistance.

Pharmacists can also ensure proper education and selection of therapy before and after discharge.

Older adults without a Part D plan face costs ranging from $180 to $295 per shot.

Regardless of a pharmacist’s practice site or type, they play an integral role in ensuring the treatment success of patients with HIV.

Pharmacists involvement in HIV care and treatment has been shown to lead to clinically and statistically significant improvements in ART adherence, as well as greater viral load suppression for patients with HIV.

Pharmacists play a vital role in HIV care by addressing social determinants of health, managing complex HIV medication regimens, and providing comprehensive patient counseling.

This step-by-step primer describes the implementation process for β-lactam TDM.

Data show these cases pose some of the most significant threats to patients and health systems.

Delivery, manufacturing concerns hinder green light from US Agency, but European Medicines Agency approves treatment.

Continued advancements in therapy may expand its use to larger patient population, though challenges remain

Vaccination provides an opportunity to prevent and treat herpes simplex virus infection.

Pediatric guidelines suggest 10 days of therapy for community-acquired pneumonia, but recent data support shortening therapy duration.

Outpatient treatment is primarily based on patient-specific factors, whereas oseltamivir remains the therapy of choice for inpatient settings.

This inflammation of the colon poses a substantial burden to patients and the health care system.

They play an indispensable role in the vaccination and management of complex regimens.

Best practices call for referring to resources, such as those from HHS and the University of Liverpool.

Monoclonal antibodies and emerging agents may avert severe illness, especially for high-risk individuals.

Duration of therapy may be just 5 to 6 days for patients without risk factors for complications.

PrEP simplifies management of the virus by eliminating the need for immune globulin and decreasing the number of doses needed.

Consider key elements of acute bacterial skin and skin structure infection to help patients manage this broad range of diseases.

FDA approval of 2-drug injectable Cabenuva is a game changer in maintaining viral suppression in patients.

Developing an antimicrobial stewardship program is arduous but valuable; commitment from leadership is the first step.

Empiric anti-MRSA therapy is an area of opportunity for antimicrobial stewardship in the treatment of CAP.